• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Failure of Medtronic’s Symplicity-3 trial doesn’t mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

Failure of Medtronic’s Symplicity-3 trial doesn’t mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 By MassDevice Contributors Network

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

Renal denervation isn't dead, despite Medtronic trial's failure

The failure of Medtronic’s Symplicity-3 trial earlier this year doesn’t mean the end of renal denervation for hypertension, especially in Europe.

That’s because physicians there, where the procedure is approved, have come to rely on it to treat patients whose high blood pressure doesn’t respond to medications. But the rigorous structure of the Symplicity-3 trial, which included a sham control arm, set a high bar for future studies. Read more

Baxter says HQ will stay in Illinois, stays coy on Boston plans

August 29, 2014 by Brad Perriello

Baxter says HQ will stay in Illinois, stays coy on Boston plans

Baxter yesterday sought to quell rumors that it’s planning to move its headquarters to Boston, saying it will maintain its home base in Deerfield, Ill., even after the spinout of its pharmaceuticals business.

Speculation on the potential move was prompted yesterday by a Boston Business Journal report that Massachusetts officials were working on a secret plan dubbed “Project Tiger” to lure Baxter to the Bay State. Read more

Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

September 3, 2014 by Brad Perriello

Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

The private equity owners of a trio of wound care and regenerative medicine companies said today that they’re merging Kinetic Concepts Inc., Systagenix and LifeCell into a single entity called Acelity.

“Coming together as a united company enables us to deliver on our vision of restoring people’s lives with a portfolio of complementary healing solutions. The combined knowledge of our team and global footprint allow us to continue advancing standards of patient care,” president & CEO Joe Woody said in prepared remarks. “We are committed to our mission of developing a portfolio of solutions that speed healing, reduce complications and lead the industry in quality, safety and customer experience.” Read more

Filed Under: News Well, Wall Street Beat Tagged With: Acelity, Apax Partners, Baxter, Boston Scientific, Centaur Guernsey, Covidien, Kinetic Concepts Inc., Kona Medical, LifeCell Corp., ReCor Medical, stjudemedical, Systagenix Wound Management Inc.

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy